1. Investment Snapshot

2. Thesis

3. Valuation & Price Target

4. Business & Product Moat

5. People & Governance

6. Market & Macro

7. Financial Quality

8. Risk Register

9. Prediction Market

10. 𝕏 Posts

Discussion

Odyssey Therapeutics, Inc. (ODTX) IPO | IPOSignal

Sections

1. Investment Snapshot

2. Capital Structure

3. What does Odyssey Therapeutics, Inc. do?

4. Valuation

Discussion

Inline comments

Investment Snapshot

Capital Structure

What does Odyssey Therapeutics, Inc. do?

Valuation

Discussion

Odyssey Therapeutics, Inc.

Analyst research, target price, syndicate analytics, and valuation sections are included with an active subscription. View plans

Investment Snapshot

424B4 All Filings

Symbol

ODTX

Event Date

2026-05-08

Sector

Health Care

Subsector

Biotechnology

Offer Range

—

Shares Offered

239M

Shares Outstanding Pre-IPO

258.89M

Total Shares Post-IPO

258.89M

Market Cap

—

Target Price

$00.00

Implied Upside vs Midpoint

$00.00

Description

Odyssey Therapeutics (ODTX) develops small‑molecule and protein therapeutics aimed at innate immune signaling and upstream immune nodes in immune‑mediated and interferon‑mediated diseases, using a discovery stack that blends AI/ML, proteomics, and conventional approaches. The equity story is concentrated in two programs: OD‑001 (oral RIPK2 scaffolding inhibitor; completed Phase 2a proof‑of‑concept in ulcerative colitis) and OD‑002 (oral SLC15A4 inhibitor; in IND‑enabling studies). Non‑recurring collaboration or license revenue could extend runway, but the primary value driver is clinical execution as internal assets move from early proof points toward later‑stage data and, potentially, partnering. Financially, Odyssey has limited operating revenue ($2.976M in 2025) against substantial spend (net loss $148.647M in 2025), with $216.6M of cash at 12/31/2025 and an accumulated deficit of ~$568.1M. Management expects cash plus offering proceeds to fund operations into H2 2028; the underwriting focus is whether the IPO pricing compensates investors for a capital‑intensive pipeline where downside is driven by development timelines and trial outcomes rather than near‑term revenue conversion. **Valuation Verdict:** The company is being asked to clear a clinical‑stage bar: valuation support will depend on conviction in OD‑001’s ability to translate Phase 2a ulcerative colitis signals into a registrational path and OD‑002’s IND‑enabling progress, rather than current revenue levels. **Catalyst Timeline:** OD‑001 post‑Phase 2a next‑step development decisions and OD‑002’s transition out of IND‑enabling work are the key visible inflection points that can re-rate the story. **Growth & Margin Trajectory:** With operating revenue at $2.976M in 2025 and net loss of $148.647M, the model is not in a margin‑expansion phase; any meaningful improvement would require either sizeable partnership economics or later‑stage clinical success that changes the financing cadence. **Governance & Operational Risk:** Cash of $216.6M at 12/31/2025 and an accumulated deficit of ~$568.1M underscore financing and execution risk typical of this stage, with outcomes heavily dependent on trial design, timelines, and the ability to prioritize programs as data emerge. **Scenario Targets:** Base‑case underwriting hinges on continued progress on OD‑001 and OD‑002 without major delays; upside comes from partnerable data that reduces capital intensity, while downside follows from weaker follow‑on efficacy/safety readthroughs or extended development timelines that raise future dilution risk.

Capital Structure

Post-IPO economic shares by class.

Class	Shares	% Economic
Common Stock (listed) 1 vote per share (assumed; not explicitly stated)	21.7M	8.4%
Series A convertible preferred stock Convertible into common stock (pro forma conversion included in aggregate conversion to common)	43.73M	16.9%
Series B convertible preferred stock Convertible into common stock (pro forma conversion included in aggregate conversion to common)	26.6M	10.3%
Series C convertible preferred stock Convertible into common stock (pro forma conversion included in aggregate conversion to common)	24.9M	9.6%
Series D convertible preferred stock Convertible into common stock (pro forma conversion included in aggregate conversion to common)	141.95M	54.8%
Total economic shares	258.89M	100%

What does Odyssey Therapeutics, Inc. do?

Financially, Odyssey has limited operating revenue ($2.976M in 2025) against substantial spend (net loss $148.647M in 2025), with $216.6M of cash at 12/31/2025 and an accumulated deficit of ~$568.1M. Management expects cash plus offering proceeds to fund operations into H2 2028; the underwriting focus is whether the IPO pricing compensates investors for a capital‑intensive pipeline where downside is driven by development timelines and trial outcomes rather than near‑term revenue conversion.

Valuation Verdict

The company is being asked to clear a clinical‑stage bar: valuation support will depend on conviction in OD‑001’s ability to translate Phase 2a ulcerative colitis signals into a registrational path and OD‑002’s IND‑enabling progress, rather than current revenue levels.

Catalyst Timeline

OD‑001 post‑Phase 2a next‑step development decisions and OD‑002’s transition out of IND‑enabling work are the key visible inflection points that can re-rate the story.

Growth & Margin Trajectory

With operating revenue at $2.976M in 2025 and net loss of $148.647M, the model is not in a margin‑expansion phase; any meaningful improvement would require either sizeable partnership economics or later‑stage clinical success that changes the financing cadence.

Governance & Operational Risk

Cash of $216.6M at 12/31/2025 and an accumulated deficit of ~$568.1M underscore financing and execution risk typical of this stage, with outcomes heavily dependent on trial design, timelines, and the ability to prioritize programs as data emerge.

Scenario Targets

Base‑case underwriting hinges on continued progress on OD‑001 and OD‑002 without major delays; upside comes from partnerable data that reduces capital intensity, while downside follows from weaker follow‑on efficacy/safety readthroughs or extended development timelines that raise future dilution risk.

Valuation

████████████████████